

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



EVEREST MEDICINES

云 頂 新 耀

Everest Medicines Limited

雲 頂 新 耀 有 限 公 司

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 1952)

POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON MONDAY, 31 OCTOBER 2022

Reference is made to the circular (the “**Circular**”) of Everest Medicines Limited (the “**Company**”) incorporating, amongst others, the notice (the “**Notice**”) of the extraordinary general meeting of the Company (the “**EGM**”) dated 14 October 2022. Unless the context requires otherwise, the capitalized terms used herein shall have the same meanings as those defined in the Circular.

At the EGM held on 31 October 2022, the proposed resolution as set out in the Notice was duly passed by the Shareholders by way of poll. The poll results in respect of the resolution proposed at the EGM are as follows:

Ordinary Resolution		Number of Votes (%)	
		For	Against
1.	To approve, confirm and ratify the Termination and Transition Services Agreement and the Transaction and authorise any one Director for and on behalf of the Company to execute and deliver all such documents, instruments and agreements and to take all steps as he or she considers necessary, desirable or expedient to implement and/or give effect to the Termination and Transition Services Agreement and the Transaction.	198,595,744 (100%)	0 (0%)

Notes:

- As a majority of the votes were cast in favour of the resolution numbered 1, such resolution was duly passed as ordinary resolution of the Company at the EGM.
- As at the date of the EGM, the total number of shares of the Company (the “**Shares**”) in issue was 307,257,033 Shares, being the total number of Shares entitling the holders to attend and vote for or against the resolution proposed at the EGM. The full text of the aforesaid resolution was set out in the Circular.
- No shareholder of the Company was required under the Listing Rules to abstain from voting on the resolution at the EGM.

- (d) None of the shareholders of the Company have stated their intention in the Circular to vote against or to abstain from voting on any of the resolution at the EGM.
- (e) The Company's Hong Kong share registrar, Computershare Hong Kong Investor Services Limited, acted as the scrutineer for the vote-taking at the EGM.
- (f) Mr. Ian Ying Woo, Mr. Xiaofan Zhang and Mr. Yifan Li have attended the EGM in person and Mr. Yongqing Luo, Mr. Yubo Gong and Ms. Lan Kang, have attended the EGM through the telecommunication facilities.

By order of the Board
Everest Medicines Limited
Wei Fu
Chairman and Executive Director

Hong Kong, 31 October 2022

As at the date of this announcement, the Board comprises Mr. Wei Fu as Chairman and Executive Director, Mr. Yongqing Luo, Mr. Ian Ying Woo and Mr. Xiaofan Zhang as Executive Directors, Mr. Yubo Gong and Ms. Lan Kang as Non-executive Directors, and Mr. Bo Tan, Mr. Yifan Li and Mr. Shidong Jiang as Independent Non-executive Directors.